{"schema_version":"1.0","type":"article","title":"Taiwan's TLC590 Beats Exparel Head-to-Head in Post-Surgical Pain","url":"https://drugnews.com.tw/articles/2026-10-23-tlc590-exparel-postsurgical-pain-phase3-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-23-tlc590-exparel-postsurgical-pain-phase3-en.md","lang":"en","date":"2026-10-23","publish_at":"2026-10-23T08:00:00+08:00","updated_at":"2026-10-23","category":"商業分析系列","topic":"公司研究","tags":["post-surgical pain","TLC590","TLC-KY","Exparel","non-opioid painkiller"],"summary":"Viatris just paid $1.65B for Exparel's maker. Eleven days later, Taiwan's TLC590 beat Exparel head-to-head in Phase 3: less pain, fewer opioids, still significant at 168 hours.","key_points":["By December 31, 2027, TLC-KY (7924) will sign a US licensing deal for TLC590 with an upfront payment above the $30 million it received for TLC599 from Endo in 2022, on the strength of Phase 3 data released October 19, 2026 showing TLC590 beat Exparel head-to-head on secondary endpoints.","TLC590's 304-patient Phase 3 bunionectomy trial met its primary endpoint versus placebo (72-hour pain, p=0.0024) and beat Exparel on 72-hour pain (p=0.0202) and opioid use (p=0.0177), with lower pain still significant at 168 hours (p=0.0226).","Viatris agreed on October 8, 2026 to acquire Exparel maker Pacira for $36.50 per share, about $1.65 billion; Exparel net sales were $575.1 million in 2025 and $147.8 million in Q2 2026, up 3% year over year."],"facts":[{"claim":"TLC590 Phase 3 enrolled patients","value":304,"unit":"patients","as_of":"2026-10-19","source":"https://udn.com/news/story/7241/9824345"},{"claim":"TLC590 vs placebo, 72-hour overall pain p-value (primary)","value":0.0024,"unit":"p-value","as_of":"2026-10-19","source":"https://udn.com/news/story/7241/9824345"},{"claim":"TLC590 vs placebo, rescue opioid use p-value","value":0.0109,"unit":"p-value","as_of":"2026-10-19","source":"https://udn.com/news/story/7241/9824345"},{"claim":"TLC590 vs Exparel, 72-hour overall pain p-value (secondary)","value":0.0202,"unit":"p-value","as_of":"2026-10-19","source":"https://udn.com/news/story/7241/9824345"},{"claim":"TLC590 vs Exparel, rescue opioid use p-value (secondary)","value":0.0177,"unit":"p-value","as_of":"2026-10-19","source":"https://udn.com/news/story/7241/9824345"},{"claim":"TLC590 vs placebo, 168-hour overall pain p-value","value":0.0168,"unit":"p-value","as_of":"2026-10-19","source":"https://udn.com/news/story/7241/9824345"},{"claim":"TLC590 vs Exparel, 168-hour overall pain p-value","value":0.0226,"unit":"p-value","as_of":"2026-10-19","source":"https://udn.com/news/story/7241/9824345"},{"claim":"Viatris offer price per Pacira share","value":36.5,"unit":"USD","as_of":"2026-10-08","source":"https://www.indianpharmapost.com/ma/viatris-to-acquire-pacira-biosciences-for-165-billion-bolstering-non-opioid-pain-treatment-portfolio-22115"},{"claim":"Viatris–Pacira deal value","value":1.65,"unit":"USD billion","as_of":"2026-10-08","source":"https://www.indianpharmapost.com/ma/viatris-to-acquire-pacira-biosciences-for-165-billion-bolstering-non-opioid-pain-treatment-portfolio-22115"},{"claim":"Exparel net product sales, 2025","value":575.1,"unit":"USD million","as_of":"2026-02-26","source":"https://investor.pacira.com/node/19206"},{"claim":"Exparel net product sales, 2024","value":549,"unit":"USD million","as_of":"2026-02-26","source":"https://investor.pacira.com/node/19206"},{"claim":"Exparel net product sales, Q2 2026","value":147.8,"unit":"USD million","as_of":"2026-08-04","source":"https://www.sec.gov/Archives/edgar/data/0001396814/000162828026052527/pcrx-06302026x991.htm"},{"claim":"Exparel net product sales, H1 2026","value":291.1,"unit":"USD million","as_of":"2026-08-04","source":"https://www.sec.gov/Archives/edgar/data/0001396814/000162828026052527/pcrx-06302026x991.htm"},{"claim":"Journavx revenue, Q2 2026","value":50,"unit":"USD million","as_of":"2026-08-05","source":"https://www.managedhealthcareexecutive.com/view/acute-pain-drug-journavx-helps-drive-vertex-growth-in-second-quarter"},{"claim":"Journavx revenue growth Q2 vs Q1 2026","value":71,"unit":"%","as_of":"2026-08-05","source":"https://www.managedhealthcareexecutive.com/view/acute-pain-drug-journavx-helps-drive-vertex-growth-in-second-quarter"},{"claim":"Journavx prescriptions filled, H1 2026","value":"約 90 萬","unit":"prescriptions (~900,000)","as_of":"2026-08-05","source":"https://www.managedhealthcareexecutive.com/view/acute-pain-drug-journavx-helps-drive-vertex-growth-in-second-quarter"},{"claim":"Zynrelef net product sales, Q2 2026","value":11.1,"unit":"USD million","as_of":"2026-08-10","source":"https://ir.herontx.com/node/17851"},{"claim":"TLC599 upfront payment from Endo (2022)","value":30,"unit":"USD million","as_of":"2022-06-13","source":"https://www.newswire.ca/news-releases/endo-executes-agreement-with-tlc-to-commercialize-phase-3-orthopedic-product-for-the-treatment-of-osteoarthritis-knee-pain-853434315.html"},{"claim":"TLC599 Endo deal upfront plus milestones cap","value":140,"unit":"USD million","as_of":"2022-06-13","source":"https://www.newswire.ca/news-releases/endo-executes-agreement-with-tlc-to-commercialize-phase-3-orthopedic-product-for-the-treatment-of-osteoarthritis-knee-pain-853434315.html"},{"claim":"TLC599 Japan licensing deal total value cap","value":203,"unit":"USD million","as_of":"2026-10-19","source":"https://udn.com/news/story/7252/9822494"},{"claim":"TLC-KY emerging-board reference price per share","value":200,"unit":"TWD","as_of":"2026-06-25","source":"https://udn.com/news/story/7254/9589022"},{"claim":"TLC590-related patents","value":"90 餘件","unit":"90+ patents","as_of":"2026-10-19","source":"https://udn.com/news/story/7241/9824345"},{"claim":"TLC590 hernia-repair study: share of patients needing no rescue opioids","value":58.3,"unit":"%","as_of":"2026-10-19","source":"https://www.tlcbio.com/en/pipeline/TLC590"},{"claim":"TLC590 hernia-repair study: reduction in mean total opioid consumption vs ropivacaine through 96 hours","value":54,"unit":"%","as_of":"2026-10-19","source":"https://www.tlcbio.com/en/pipeline/TLC590"}],"sections":["01 | The three worst days after surgery","02 | One yardstick, four non-opioid options","03 | What TLC590 proved","04 | Viatris just bought Exparel, and that raises TLC590's price","05 | The Taiwan angle: from delisting to a Phase 3 win","Taiwan stock link","References"],"references":[{"title":"TLC新藥三期大勝、碾壓美國主流藥 挾Best in Class優勢搶攻百億商機","source":"Economic Daily News (udn.com","date":"2026-10-19","url":"https://udn.com/news/story/7241/9824345"},{"title":"TLC-KY長效止痛新藥解盲成功 預計最快明年底美國上市","source":"Liberty Times","date":"2026-10-19","url":"https://ec.ltn.com.tw/article/breakingnews/5611408"},{"title":"TLC停牌 新藥解盲聚焦","source":"Economic Daily News (udn.com","date":"2026-10-19","url":"https://udn.com/news/story/7252/9822494"},{"title":"快訊／注意！這家生技股下午4點召開重訊 說明新藥解盲結果","source":"SETN","date":"2026-10-19","url":"https://www.setn.com/news/1924944"},{"title":"Viatris to acquire Pacira BioSciences for $1.65 billion bolstering non-opioid pain treatment portfolio","source":"Indian Pharma Post","date":"2026-10-11","url":"https://www.indianpharmapost.com/ma/viatris-to-acquire-pacira-biosciences-for-165-billion-bolstering-non-opioid-pain-treatment-portfolio-22115"},{"title":"Viatris communications regarding tender offer for Pacira (Form SC TO-C, Ex.99.1","source":"SEC","date":"2026-10-08","url":"https://www.sec.gov/Archives/edgar/data/0001396814/000114036126039148/ef20083527_ex99-1.htm"},{"title":"Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results","source":"Pacira BioSciences","date":"2026-02-26","url":"https://investor.pacira.com/node/19206"},{"title":"Pacira BioSciences Q2 2026 results (Form 8-K, Ex.99.1","source":"SEC","date":"2026-08-04","url":"https://www.sec.gov/Archives/edgar/data/0001396814/000162828026052527/pcrx-06302026x991.htm"},{"title":"Acute pain drug Journavx helps drive Vertex growth in second quarter","source":"Managed Healthcare Executive","date":"2026-08-05","url":"https://www.managedhealthcareexecutive.com/view/acute-pain-drug-journavx-helps-drive-vertex-growth-in-second-quarter"},{"title":"Vertex Announces FDA Approval of JOURNAVX (suzetrigine), a First-in-Class Treatment for Moderate-to-Severe Acute Pain","source":"Vertex Pharmaceuticals","date":"2025-01-30","url":"https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-fda-approval-journavxtm-suzetrigine-first-class"},{"title":"Heron Therapeutics Announces Second Quarter 2026 Financial Results","source":"Heron Therapeutics","date":"2026-08-10","url":"https://ir.herontx.com/node/17851"},{"title":"Heron Therapeutics combo drug for post-surgical pain wins FDA nod on third try","source":"MedCity News","date":"2021-05-13","url":"https://medcitynews.com/2021/05/heron-therapeutics-combo-drug-for-post-surgical-pain-wins-fda-nod-on-third-try/"},{"title":"Endo Executes Agreement with TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain","source":"Endo International (Cision","date":"2022-06-13","url":"https://www.newswire.ca/news-releases/endo-executes-agreement-with-tlc-to-commercialize-phase-3-orthopedic-product-for-the-treatment-of-osteoarthritis-knee-pain-853434315.html"},{"title":"台微體改名TLC-KY重新登興櫃…每股參考價200元 創今年生技股掛牌新高","source":"Economic Daily News (udn.com","date":"2026-06-25","url":"https://udn.com/news/story/7254/9589022"},{"title":"TLC590 pipeline page","source":"TLC BioSciences","date":"2026-10-19","url":"https://www.tlcbio.com/en/pipeline/TLC590"},{"title":"TLC-KY明登興櫃 每股參考價200元 雙三期新藥拚授權","source":"Commercial Times","date":"2026-06-25","url":"https://www.ctee.com.tw/news/20260625701728-430503"},{"title":"TLC-KY術後止痛新藥TLC590三期完成收案 解盲倒數 搶攻706億美元市場","source":"Commercial Times","date":"2026-07-30","url":"https://www.ctee.com.tw/news/20260730701681-430504"}],"images":[{"alt":"Fig. 1 | Three painkillers, one gate","url":"https://drugnews.com.tw/assets/articles/tlc590-exparel-postsurgical-pain-phase3-en/figure-01.png"},{"alt":"Fig. 2 | Who actually makes money","url":"https://drugnews.com.tw/assets/articles/tlc590-exparel-postsurgical-pain-phase3-en/figure-02.png"},{"alt":"Fig. 3 | The Phase 3 results at a glance","url":"https://drugnews.com.tw/assets/articles/tlc590-exparel-postsurgical-pain-phase3-en/figure-03.png"},{"alt":"Fig. 4 | TLC590's road map","url":"https://drugnews.com.tw/assets/articles/tlc590-exparel-postsurgical-pain-phase3-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/tlc590-exparel-postsurgical-pain-phase3-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-23）。Taiwan's TLC590 Beats Exparel Head-to-Head in Post-Surgical Pain。https://drugnews.com.tw/articles/2026-10-23-tlc590-exparel-postsurgical-pain-phase3-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}